Yuxuan Wu

Yuxuan Wu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2022 in Nature
Verified
Journal Article
Open access
PDF file
JZJiqin Zhang
Jiqin Zhang
YHYongxian Hu
Yongxian Hu
JYJiaxuan Yang
Jiaxuan Yang
WLWei Li
Wei Li
MZMingming Zhang
Mingming Zhang
HHHe Huang
He Huang
Recently, chimeric antigen receptor (CAR)-T cell therapy has shown great promise in treating haematological malignancies1–7. However, CAR-T cell therapy currently has several limitations8–12. Here we successfully developed a two-in-one approach to generate non-viral, gene-specific targeted CAR-T cells through CRISPR–Cas9. Using the optimized protocol, we demonstrated feasibility in a preclinical study by inserting an anti-CD19 CAR cassette into the AAVS1 safe-harbour locus. Furthermore, an innovative type of anti-CD19 CAR-T cell with PD1 integration was developed and showed superior ability to eradicate tumour cells in xenograft models. In adoptive therapy for relapsed/refractory aggressive B cell non-Hodgkin lymphoma (ClinicalTrials.gov, NCT04213469), we observed a high rate (87.5%) of complete remission and durable responses without serious adverse events in eight patients. Notably, these enhanced CAR-T cells were effective even at a low infusion dose and with a low percentage of CAR+ cells. Single-cell analysis showed that the electroporation method resulted in a high percentage of memory T cells in infusion products, and PD1 interference enhanced anti-tumour immune functions, further validating the advantages of non-viral, PD1-integrated CAR-T cells. Collectively, our results demonstrate the high safety and efficacy of non-viral, gene-specific integrated CAR-T cells, thus providing an innovative technology for CAR-T cell therapy.

4 August 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BFBin Fu
Bin Fu
JLJiaoyang Liao
Jiaoyang Liao
SCShuanghong Chen
Shuanghong Chen
WLWei Li
Wei Li
QWQiudao Wang
Qiudao Wang
YWYuxuan Wu
Yuxuan Wu

13 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJiaoyang Liao
Jiaoyang Liao
SCShuanghong Chen
Shuanghong Chen
SHShenlin Hsiao
Shenlin Hsiao
YJYanhong Jiang
Yanhong Jiang
YYYang Yang
Yang Yang
YWYuxuan Wu
Yuxuan Wu
In β-thalassemia, either γ-globin induction to form fetal hemoglobin (α2γ2) or β-globin repair to restore adult hemoglobin (α2β2) could be therapeutic. ABE8e, a recently evolved adenine base editor variant, can achieve efficient adenine conversion, yet its application in patient-derived hematopoietic stem cells needs further exploration. Here, we purified ABE8e for ribonucleoprotein electroporation of β-thalassemia patient CD34+ hematopoietic stem and progenitor cells to introduce nucleotide substitutions that upregulate γ-globin expression in the BCL11A enhancer or in the HBG promoter. We observed highly efficient on-target adenine base edits at these two regulatory regions, resulting in robust γ-globin induction. Moreover, we developed ABE8e-SpRY, a near-PAMless ABE variant, and successfully applied ABE8e-SpRY RNP to directly correct HbE and IVS II-654 mutations in patient-derived CD34+ HSPCs. Finally, durable therapeutic editing was produced in self-renewing repopulating human HSCs as assayed in primary and secondary recipients. Together, these results support the potential of ABE-mediated base editing in HSCs to treat inherited monogenic blood disorders.

3 March 2026 in Nature Medicine
Verified
Journal Article
Closed access
PWPing Wan
Ping Wan
STSiyuan Tang
Siyuan Tang
DLDongni Lin
Dongni Lin
YLYuming Lu
Yuming Lu
MLMei Long
Mei Long
QXQiang Xia
Qiang Xia

28 December 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JWJiaxin Wu
Jiaxin Wu
JLJuan Li
Juan Li
KCKang Chen
Kang Chen
GLGuolong Liu
Guolong Liu
YZYating Zhou
Yating Zhou
TZTao P. Zhong
Tao P. Zhong
Hematopoietic stem and progenitor cells (HSPCs) are a heterogeneous group of cells with expansion, differentiation, and repopulation capacities. How HSPCs orchestrate the stemness state with diverse lineage differentiation at steady condition or acute stress remains largely unknown. Here, we show that zebrafish mutants that are deficient in an epigenetic regulator Atf7ip or Setdb1 methyltransferase undergo excessive myeloid differentiation with impaired HSPC expansion, manifesting a decline in T cells and erythroid lineage. We find that Atf7ip regulates hematopoiesis through Setdb1-mediated H3K9me3 modification and chromatin remodeling. During hematopoiesis, the interaction of Atf7ip and Setdb1 triggers H3K9me3 depositions in hematopoietic regulatory genes includingcebpβandcdkn1a, preventing HSPCs from loss of expansion and premature differentiation into myeloid lineage. Concomitantly, loss of Atf7ip or Setdb1 derepresses retrotransposons that instigate the viral sensor Mda5/Rig-I like receptor (RLR) signaling, leading to stress-driven myelopoiesis and inflammation. We find that ATF7IP or SETDB1 depletion represses human leukemic cell growth and induces myeloid differentiation with retrotransposon-triggered inflammation. These findings establish that Atf7ip/Setdb1-mediated H3K9me3 deposition constitutes a genome-wide checkpoint that impedes the myeloid potential and maintains HSPC stemness for diverse blood cell production, providing unique insights into potential intervention in hematological malignancy.

12 August 2025 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
SXSaijuan Xu
Saijuan Xu
DLDan Liang
Dan Liang
QWQiudao Wang
Qiudao Wang
YCYan Cheng
Yan Cheng
DXDa Xie
Da Xie
YWYuxuan Wu
Yuxuan Wu